𝔖 Bobbio Scriptorium
✦   LIBER   ✦

How to use clinical vignettes in hematology—A pilot survey in the context of chronic lymphocytic leukemia

✍ Scribed by Sandra M. Camps; Sylvie Chevret; Vincent Lévy


Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
159 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

✦ Synopsis


Rationale:

Case vignettes have been validated as an efficient tool for assessing the quality of clinical practices, and have been used in a variety of medical settings. however, their use in the field of hematology has not been tested.

Objectives:

We undertook a study to pre-test seven case vignettes, and thereby to assess practice patterns and, when possible, guideline adherence in the treatment of chronic lymphocytic leukemia (cll) by french hematologists.

Findings:

Of the 64 hematologists who agreed to participate, 26 (41%) completed the vignettes. we found significant differences in the physicians' patterns of ordering further investigations among young and old patients in the same clinical context. this is not consistent with published guidelines. moreover, the most striking differences concerned the physicians' interpretations of prognostic factors and the use of radiological testing before treatment. modalities of treatment were variable across clinical situations, especially with regard to second-line treatments. clinicians understood the vignettes well, except for those that dealt with stem cell transplantation.

Conclusions:

This pilot study showed the feasibility of the use of case vignettes to assess the quality of clinical practice in cll. the initial results identified deviations from the published guidelines. a large-scale european survey will commence in a few months.


📜 SIMILAR VOLUMES


Routine clinical use of alemtuzumab in p
✍ Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono